Elevance Health tops Q3 estimates as medical costs ease
Elevance Health moved into the final stretch of 2026 with a stronger earnings profile, reporting $1.4 billion in third-quarter profit and raising its full-year outlook after a period of uneven managed care margins across the industry. Revenue held essentially flat year over year at $50.4 billion, but the payer’s bottom line improved enough to support a higher earnings forecast and a more confident stance on next year’s growth trajectory.
The quarter offered a cleaner read on the company’s operating rhythm than many payers have seen in recent reporting cycles. A lower medical loss ratio signaled that claims expense is coming into better balance with premium income, even as membership continued to shrink in several lines of business. For health insurers, that combination matters: disciplined cost control can lift margins quickly, but premium growth is harder to sustain when enrollment weakens in core government and employer segments.
Medicare Advantage and the individual market drove the MLR improvement
Elevance reported a third-quarter medical loss ratio of 90.6%, down from 91.7% in the same quarter of 2025. The company tied the improvement to stronger performance in both Medicare Advantage and the individual market, two areas that have been under intense cost pressure across the sector. In practical terms, a lower MLR means a larger share of premium dollars is being retained after medical claims are paid, giving the insurer more room to absorb administrative expense and support earnings growth.
The improvement came after a stretch in late 2024 and 2025 when MLR performance weighed on much of the industry. Elevance’s results suggest that the company has moved further along the curve in rebalancing pricing, utilization, and benefit expense. In a business built on narrow spreads, even modest movement in the loss ratio can translate into large changes in net income.
Elevance said the gains in the third quarter reflected better performance across its diversified portfolio. The company’s Health Benefits business and Carelon division continued to operate as intertwined engines, one centered on insurance premiums and the other on care delivery, pharmacy, and risk-based services. The insurer framed that structure as a competitive advantage because it allows more control over the flow of members, claims, and ancillary services across the enterprise.
Membership declines kept a lid on top-line growth
Revenue did not surge despite the stronger profit print. Operating revenue at the insurance unit reached $43.4 billion, up from $42.2 billion a year earlier, supported by higher premium yields and service fee revenue. Those gains were partly offset by declining membership in Medicare Advantage, Medicaid, and employer group plans.
Elevance ended the quarter with about 44.9 million members, down by 487,000 from the third quarter of 2025. The decline matters because membership is the core substrate of payer revenue: fewer covered lives can blunt premium growth even when pricing improves. It also signals that Elevance is navigating a more selective enrollment environment, where the company is willing to absorb some attrition rather than chase volume at the expense of margin discipline.
The drop in membership gives a sharper edge to the company’s earnings beat. Stronger pricing and better expense management can lift profits in the near term, but sustained earnings growth will require either a stabilization in enrollment or continued gains from the Carelon platform and other fee-based operations. Without that, top-line expansion could remain restrained even if margins hold.
Carelon kept growing and remains central to the strategy
Carelon continued to provide one of the clearest growth offsets in the quarter. Operating revenue at the division rose to $19.3 billion from $18.3 billion a year earlier, driven by growth at CarelonRx and the risk-based solutions business within Carelon Services. The segment has become increasingly important as Elevance uses non-insurance operations to diversify revenue and deepen control over pharmacy and care-management economics.
The appeal is straightforward. Pharmacy benefit and risk-based service operations can generate revenue streams that are less dependent on traditional membership growth than the core insurance business, while also giving the parent company more influence over utilization patterns and downstream costs. In a managed care market where pricing power is constrained and public programs remain closely scrutinized, that kind of integration can make the difference between margin compression and expansion.
Guidance rose again, and leadership turnover followed
Elevance lifted its full-year earnings expectation to at least $29 per share, up from prior guidance of $27. The company had already raised its outlook in the second quarter, so the latest increase extends a pattern of upward revisions as the year progressed. Gail Boudreaux said the business remains on track to deliver at least 12% EPS growth in 2027 relative to the higher baseline now expected after the third quarter.
A single sentence captured the quarter’s shift: Elevance now has more earnings power than it assumed earlier in the year.
The company also announced that Jeff Park will become president of Carelon on Dec. 1. He arrives from Waltz Health, where he served as president and helped guide its merger with EVERSANA as well as growth initiatives. His prior roles at OptumRx, Catamaran, WellDyneRx and Diplomat Pharmacy give him experience across pharmacy and specialty distribution channels that overlap heavily with Carelon’s strategic priorities.
Boudreaux said Carelon sits at the center of Elevance’s growth strategy and that Park’s background should help accelerate expansion, execution and customer value. Her comments framed the appointment as both operational and strategic, reflecting the company’s effort to keep Carelon moving while the insurance side works through a more complicated membership and pricing environment.
What the quarter says about payer economics
Elevance’s third quarter was less about a dramatic turnaround than about control. The company benefited from lower medical cost pressure, steadier premium economics and continued growth in Carelon, while membership losses reminded investors that earnings strength can coexist with volume erosion. The balance between those forces will shape how durable the company’s revised guidance proves to be over the next several quarters.
One unresolved pressure point remains the same: can Elevance sustain margin gains if enrollment in Medicare Advantage, Medicaid and employer plans continues to soften? The answer will depend on whether Carelon can keep expanding fast enough to offset the drag from a smaller insured base and whether the improved MLR can hold as utilization patterns evolve heading into 2027.